BioSpace News Archive

Orasis Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%).

Cognition Therapeutics, Inc. , (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its third “Conversations” video podcast, featuring a discussion with two Lewy body dementia caregivers, who are also passionate advocates for the second most common and devastating form of dementia.

Palvella Therapeutics, Inc. today reported progress on its three lead development programs for QTORIN™ rapamycin.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023 and will provide a business update.

Harmony Biosciences today reported financial results and business updates for the fourth quarter and full year ended December 31, 2022.

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2022 on Tuesday, February 28, 2023.

Vor Bio, a clinical-stage cell and genome engineering company, announced that it will participate in the following upcoming investor conferences.

IntelGenx Corp., a leader in pharmaceutical films, announced that the United States Patent and Trademark Office has granted a Notice of Allowance for U.S. Patent Application 16/053,383, entitled “Loxapine Film Oral Dosage Form.”.

BioVie Inc. today announced that BioVie Day will be held March 23, 2023 at 10 a.m. Eastern Standard Time.

Leal Health announced today that the Company presented a poster on the negative impact of Eastern Cooperative Oncology Group (ECOG) performance status scores on cancer patients’ eligibility to enroll in clinical trials at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium.